Valuation: Agios Pharmaceuticals, Inc.

Market Cap 1.9B 1.69B 1.57B 1.43B 2.71B 183B 2.73B 19.05B 7.38B 93.3B 7.13B 6.97B 299B P/E 2026 *
-5.6x
P/E 2027 * -8.61x
Enterprise Value 1.64B 1.46B 1.36B 1.24B 2.34B 158B 2.36B 16.47B 6.38B 80.64B 6.16B 6.03B 259B EV / Sales 2026 *
8.99x
EV / Sales 2027 * 5.02x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day-2.09%
1 week-2.39%
Current month-4.36%
1 month-4.01%
3 months-15.38%
6 months-9.66%
Current year+16.83%
1 week 31.65
Extreme 31.65
34.12
1 month 31.37
Extreme 31.37
35.38
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 08/08/2022
Director of Finance/CFO 51 26/09/2022
Chief Tech/Sci/R&D Officer 47 01/09/2021
Director TitleAgeSince
Director/Board Member 66 09/12/2014
Director/Board Member 73 23/06/2015
Director/Board Member 73 27/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
8/4/26 A Sell

Chief Technology Officer

-30,000 0.0504%
7/8/26 A Free

Director

2,894 0.0049%
7/1/26 A Exercice

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%-2.39%-21.48%+32.39% 1.9B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.41%-0.77%+45.22%+118.92% 39.24B
Weighted average by Cap. +0.11%-0.85%+56.58%+137.75%

Financials

2026 *2027 *
Net sales 182M 162M 151M 138M 260M 17.54B 263M 1.83B 710M 8.97B 685M 670M 28.78B 351M 312M 291M 265M 500M 33.74B 505M 3.52B 1.36B 17.25B 1.32B 1.29B 55.35B
Net income -338M -300M -280M -256M -482M -32.5B -486M -3.39B -1.31B -16.61B -1.27B -1.24B -53.31B -230M -204M -191M -174M -328M -22.1B -331M -2.31B -894M -11.3B -863M -845M -36.26B
Net Debt -258M -229M -214M -195M -367M -24.77B -371M -2.59B -1B -12.66B -967M -946M -40.63B -137M -122M -114M -104M -196M -13.21B -198M -1.38B -534M -6.75B -516M -505M -21.67B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
02/10/26 $31.80 -2.09% 569,934
01/10/26 $32.48 -2.32% 1,703,750
30/09/26 $33.25 -0.15% 1,548,455
29/09/26 $33.30 -0.36% 416,413
28/09/26 $33.42 +2.58% 1,347,679
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
31.80USD
Average target price
46.25USD
Spread / Average Target
+45.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock